CeccantiM, BlumK, BowirratA, et al.Future newborns with opioid-induced neonatal abstinence syndrome (NAS) could be assessed with the genetic addiction risk severity (GARS) Test and potentially treated using precision amino-acid enkephalinase inhibition therapy (KB220) as a frontline modality instead of potent opioids. J Pers Med, 2022; 12:2015; doi: 10.3390/jpm12122015
